VEGFA and cancer: Although there has been lacking sufficient clinical data to convincingly correlate improvement of PNS and CCA by these drugs with clinical outcomes, I reasonably speculate that improvement of the systemic cancer disease by anti-VEGF drugs likely contributes to prolonged survivals of cancer patients in either monotherapy and combination therapy settings.